<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Scarlett, J.A.</title>
    <link>http://repub.eur.nl/res/aut/10946/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient (Article)</title>
      <link>http://repub.eur.nl/res/pub/9570/</link>
      <pubDate>2001-01-01T00:00:00Z</pubDate>
      <description>We describe the case of an acromegalic subject, who was the first patient
          ever treated with the GH receptor antagonist pegvisomant. Furthermore, in
          this particular patient, progression in tumor size was encountered during
          treatment with pegvisomant. The patient described did benefit from
          cotreatment with pegvisomant and octreotide, including decreased GH
          levels, normalization of serum insulin-like growth factor I
          concentrations, and improvement of visual field defects.</description>
    </item>
  </channel>
</rss>